Mr. Elliot McKerr reports

HYTN SIGNS AGREEMENT TO ACQUIRE PRISM SCIENTIFIC LABS INC.

HYTN Innovations Inc. has entered into an agreement (the purchase agreement) to acquire (the transaction) 100 per cent of the issued and outstanding share capital of Prism Scientific Labs Inc. in consideration for an aggregate of 12,100,100 common shares of the company. All the vendor shareholders of Prism are arm's length to the company, and no new insider or control person will be created as a result of the transaction.

Prism is the holder of licensed intellectual property which pertains to a proprietary blend of narrow bandwidth visible and non-visible light spectrums, arranged in a configuration designed to enhance nutrient density, growth speed and overall yield in non-photosynthetic organisms, specifically those producing psilocybin, psilocin and related tryptamine alkaloids.

Closing is subject to several standard closing conditions, including receipt of regulatory approvals.

About HYTN Innovations Inc.

HYTN formulates, manufactures, markets and sells premium products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids. HYTN's mission is to become the top provider of these products in all markets where such products are federally regulated. To achieve this, the company focuses on identifying market opportunities and quickly bringing its innovative products to market through its elevated development platform.

We seek Safe Harbor.